1. Home
  2. BIRK vs GKOS Comparison

BIRK vs GKOS Comparison

Compare BIRK & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Birkenstock Holding plc

BIRK

Birkenstock Holding plc

HOLD

Current Price

$35.60

Market Cap

6.1B

Sector

N/A

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$106.37

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BIRK
GKOS
Founded
1774
1998
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.1B
6.0B
IPO Year
2023
2015

Fundamental Metrics

Financial Performance
Metric
BIRK
GKOS
Price
$35.60
$106.37
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
14
Target Price
$62.69
$133.07
AVG Volume (30 Days)
2.2M
557.1K
Earning Date
02-12-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$507,442,000.00
Revenue This Year
$13.71
$23.34
Revenue Next Year
$14.21
$27.46
P/E Ratio
$17.48
N/A
Revenue Growth
N/A
32.33
52 Week Low
$33.06
$73.16
52 Week High
$57.39
$130.23

Technical Indicators

Market Signals
Indicator
BIRK
GKOS
Relative Strength Index (RSI) 41.05 47.78
Support Level N/A $104.72
Resistance Level $42.19 $113.50
Average True Range (ATR) 1.48 3.94
MACD -0.42 -0.16
Stochastic Oscillator 28.85 49.38

Price Performance

Historical Comparison
BIRK
GKOS

About BIRK Birkenstock Holding plc

Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: